Programme

Day 0 – Tuesday, November 21

18.30-21.00

Meet and greet

Hotel restaurant

  • Organizers and speakers of the conference meet the early guests

 


Day 1 – Wednesday, November 22

9.00-10.30

Conference opening

Plenary session – Main hall, screening to halls 1 and 2

Welcome speeches by keynote speakers and partners of the conference

Chair:
  • Jindřich Vobořil (National Drug Coordinator of the Czech Republic (aka “Czech drug czar”)
Speakers:
  • Michel Kazatchkine (member of the Global Commission on Drug Policy, and United Nations Secretary-General’s Special Envoy for AIDS in Eastern Europe and Central Asia)
  • Steph Sherer (Americans for Safe Access, and International Medical Cannabis Patients Consortium)
  • Ben Bronfman (Discorides Global Holdings)
  • Svatopluk Němeček (Czech Minister of Health 2014-2016, and Director of the Faculty Hospital in Ostrava)
  • Miroslava Němcová (Member of the Chamber of Commons, Czech Parliament)
  • Lumír Ondřej Hanuš (Hebrew University in Jerusalem, and The Lambert Center for the Study of Medicinal Cannabis and Hemp, Thomas Jefferson University, Philadelphia, USA)
  • Mark Ware (McGill University, and chair of the International Association for Cannabinoids Medicines)
  • Ethan Russo (ICCI, Phytecs, Inc, formerly GW Pharmaceuticals)

10.30-11.00             Coffee break

11.00-12.30

Medical cannabis regulation in Europe

Parallel session – main hall

Medical cannabis regulation systems in the EU: rules, implementation, outputs

Chair:
  • Ingo Ilja Michels (former Head of Unit of the Ministry of Health, Germany)
  • Brendan Hughes (EMCDDA)
Speakers:
  • Representatives of the National Medical Cannabis Agencies of the EU Member States

Cannabis, cannabinoids and cancer

Parallel session – hall 1

Where are we going? Status of the research, best practices in the use, case examples of successful current treatment procedures

Chair:
  • Jan Žaloudík (oncologist, director of Masaryk Memorial Cancer Institute)
Speakers:
  • Allan Frankel (Greenbridge Medical Services) + other participants based on abstracts selection

Educate your doctor

Parallel session – hall 2

No one will do it for you. How the patients should approach the information they gather from various sources, and how shall they use them when communicating with their practicians and specialists.

Chair:
  • Richard Rokyta (President of the Czech Medical Academy)
Speaker:
  • Steph Sherer (Americans for Safe Access, International Medical Cannabis Patients Consortium)

12.30-13.30             Lunch

13.30 – 15.00

Entourage effect: whole plant works better than individual components

Plenary session – main hall, screening to halls 1 and 2

Cannabis is a plant full of interrelated molecules. Although particular cannabinoids have proven results in curing particular medical conditions, using whole plant has an entourage effect: the cannabinoid complex works better when using a plant as a whole. Does one research paradigm fit for entourage effect, too?

Chair:
  • Lumír Ondřej Hanus (Hebrew University in Jerusalem, ICCI)
Speakers:
  • Ethan Russo (ICCI, Phytecs, Inc, formerly GW Pharmaceuticals)
  • Pal Pacher (National Institute on Alcohol Abuse and Alcoholism, NIH)
  • Tomáš Zábranský (ResAd, ICCI) + other participants based on abstracts selection

15.00 – 15.30          Coffee break

15.30 – 17.00

Controversies and needs in clinical studies

Parallel session, main hall

Cannabis and cannabinoids have been subject to intense research for a long time. Although scientists and doctors see the potential, general awareness and position of cannabis has been a source of controversial reactions to regular results of the research and corresponding clinical studies. What do researchers need to continue in their perspective research?

Chair:
  • Ethan Russo (ICCI, Phytecs, Inc, formerly GW Pharmaceuticals)
Speakers:
  • Allan Frankel (Greenbridge Medical Services)
  • Tomáš Zábranský (ResAd, ICCI)
  • + other discussants based on abstracts selection

Studies of medical cannabis policies

Parallel session, hall 1

Achievements, failures, pitfalls. There are various approaches which states could adopt towards cannabis as a medicine. Although medical cannabis is legal in most of the EU countries, its availability to patients is completely different matter. How can different states approach their cannabis policy, and what are the possible outcomes in the upcoming years?

Chair:
  • Alex Stevens (University of Kent, President of the ISSDP)
Speakers:
  • Allan Frankel (Greenbridge Medical Services)
  • Tomáš Zábranský (ResAd, ICCI)
  • + other discussants based on abstracts selection

Martina Kafková: A day in the life of medical cannabis patient

Parallel session – hall 2

Martina Kafková, most “famous” Czech cannabis patient, is being denied the only working medicine. Or at least the way she gets her medicine is extremely complicated and sometimes on the verge of law.

  • Martina need around 3 grams of cannabis per day, just to survive. Current system is effectively blocking her access to it.
  • The price in pharmacies would cost her 30.000 CZK per month, while the disabled pension is only 10.000 CZK. So like most of the patients, she must rely on the black market and friends.
  • Smoking several times a day is a necessity for Martina. Even during the night, she has to wake up and smoke cannabis. Otherwise she would die.
  • Special presentation

17.00 – 18.00          Coffee break

18.00-21.00

Festive gala reception

24th floor restaurant


Day 2 – Thursday, November 23

 

9.00-10.30

Clinical research and cannabis

Plenary session – Main hall, screening to halls 1 and 2

Evidence based medicine has its limitations. The existing gap between the research and the practice is evident and creates the obstacles for successful implementation of the research into the everyday practice. What are those barriers, and how can we overcome them?

Chair:
  • Allan Frankel (Greenbridge Medical Services)
Speakers:
  • Mark Ware (McGill Uni & IACM)
  • Philippe Lucas (Tilray)
  • + other participants based on abstracts selection

10.30-11.00             Coffee break

11.00-12.30

Cannabis and big pharma

Parallel session – main hall

For decades, pharmaceutical companies have mostly rejected even the idea of cannabis-based drugs into their portfolio. Introduction of cannabinoids might significantly harm their other income streams, mostly in the area of pain treatment – but is there enough potential for cannabis to be a new drug of choice for pharma? Some companies are already delving into cannabinoids.

Chair:
  • Ethan Russo (ICCI, Phytecs, Inc, formerly GW Pharmaceuticals)
Speakers:
  • Tomáš Zábranský (ResAd, ICCI)
  • Speaker’s slots open

Medical cannabis regulation in America, Australia, Israel

Parallel session – hall 1

Regional rules, implementation, outputs

Chair:
  • Mark Ware (McGill University and IACM)
  • Nicola Singleton (EMCDDA)
Speakers:
  • Representatives of the National Medical Cannabis Agencies of the EU Member States

Substitution of opioids in pain treatment with cannabinoids

Parallel session – hall 2

It has been proven with scientific studies, that cannabinoids can be a safe substitution for opioids. The benefits include not being exposed to the risk of addiction and also not bringing your body into life-threatening situations.

Chair:
  • Radovan Hřib (Chief Medical Doctor, Centre for Pain Treatment, St. Ann’s Faculty Hospital in Brno)
Speakers:
  • Philippe Lucas (Tilray)

12.30-13.30             Lunch

13.30-15.00

What the patients need?

Parallel session – main hall

… and what are they going to do with it? Most patients feel unsafe within the system, which does not protect their rights. There are millions of patients in the society today, that could potentially benefit from the health effects of cannabis – yet the medicine, that can help them live a quality life, is not available to them. In this session, we will also stress the importance of patient’s organisations.

Chair:
  • Steph Sherer (Americans for Safe Access, International Medical Cannabis Patients Consortium)
  • Hana Vagnerova (KOPAC, Czech association of cannabis patients)
Speakers:
  • Representatives of the National Medical Cannabis Agencies of the EU Member States

Cannabis/hemp-based nutrition

Parallel session – hall 1

Legal cannabis, known as hemp, is widely considered “a healthy food”. It has great nutritional values, and can be a good addition to a balanced diet, thus add to the therapeutic recovery treatments and prevention. We will discuss the legal status of hemp food products and hemp extract rich in CBD, the appropriate means of distribution, what are the basic norms that the hemp producer must adhere to, How to use hemp products as a dietary supplement, to help recovery from illness, to help with bodybuilding and reconvalescence.

Chair:
  • Hana Gabrielová (Hempoint – CEO and partner, also member of KOPAC board)
Speakers:
  • To be specified

Medical cannabis as an political issue in the Czech republic

Parallel session – hall 2

No one will do it for you. How the patients should approach the information they gather from various sources, and how shall they use them when communicating with their practicians and specialists.

Chair:
  • Tomáš Zábranský (ResAd, ICCI)
Speakers:
  • Filip Humplík, ODS (Civic democratic party)
  • Svatopluk Němeček, ČSSD (Social democrats) – or other option from the same party
  • Ivan Bartoš, Pirate party

+ other speakers from Czech political parties


15.00 – 15.30          Coffee break

15.30-17.00

Medical cannabis regulation outside the “western” world

Parallel session – main hall

Regional rules, implementation, outputs

Chair:

Pavel Bem (Global Drug Commission)
Steph Sherer (ASA and IMCPC)

Speakers:

Representatives of the National Medical Cannabis Agencies of the respective countries


CBD – miracle compound or marketing hype?

Parallel session – hall 1

CBD is sometimes considered “the other miracle cannabinoid”, next to THC. In fact, the only reason why there are so many CBD-related businesses is the legality of the compound – CBD is legal, THC is not. Although CBD has proven to have medical effect, many producers market is as a panacea. Which is a dangerous assumption, from many points of view.

Chair:

Pavel Kubů, MC – (ICCI, KOPAC)

Speakers:

To be specified (free speaker’s slots)


Translational research of cannabinoids: how to get the medicine out fast

Parallel session, hall 2

From preclinical studies to possible clinical use, the translational research utilizes interdisciplinary interactions to maximize the impact of using cannabinoids in both prevention and therapy.

Chair:

Alexandra Šulcová (Medical Faculty, Masaryk University in Brno)

Speakers:

Research Group of Experimental and Applied Neuropsychopharmacology in the Central European Institute of Technology, Masaryk University


17.00-17.30             Coffee break

17.30-18.30

Global regulation systems – review

Plenary session – Main hall, screening to halls 1 and 2

What regulation, what aims, what results, what recommendations – reporting from the parallel sessions

Chair:
  • Michel Kazatchkine (member of the Global Commission on Drug Policy, and United Nations Secretary-General’s Special Envoy for AIDS in Eastern Europe and Central Asia)
  • Jindřich Vobořil (National Drug Coordinator of the Czech Republic (aka “Czech drug czar”)
Speakers:
  • Ingo Ilja Michels (former Head of Unit of the Ministry of Health, Germany)
  • Brendan Hughes (EMCDDA)
  • Nicola Singleton (EMCDDA)
  • Pavel Bém (Global Commission for Drug Policy)
  • Steph Sherer (Americans for Safe Access, and International Medical Cannabis Patients Consortium)
  • Mark Ware (McGill University, and chair of the International Association for Cannabinoids Medicines)

18.30-19.30             Coffee break

19.30-late

Is EU a pasture for medical cannabis cash cows?

Working dinner arrangement / restaurant, lobby / special paid entrance

With unclaimed stakes in the cannabis territory and huge profit margins, there has never been a better time to invest.

  • The booming business. Camparison of the numbers between US and EU. Higher GDP, more citizens, higher number of patients. No central law authority, which should eventually prohibit selling medical cannabis under regional laws.
  • The US experience in the EU – can it be repeated? The synergy between US experience and sources (personal, material) and EU practice (excellent local knowledge), network of contacts of suppliers, clients and general public.
  • Germany example. The biggest and leading European country will have legal cannabis from 2018, covered fully by insurance companies. The amount of cannabis needed will be huge. Where will they get it? What are the implications for other EU and US businesses?
  • Investor’s paradise. The returns of investment in the cannabis business are tremendous, and investors are already lining up to claim the best stakes.
  • EU market benefits: market size, legal stability, synergies and high returns
Presentation:
  • Ben Bronfman (Discorides Global Holdings)
  • TBD

Day 3 – Friday, November 24

9.00-10.30

Medical Cannabis Policies and unintended consequences

Plenary session – Main hall, screening to halls 1 and 2

What are the effects and impacts of the wide scale of cannabis-related policies to patients and medical practice. This section will be focused on children, teenagers and medical cannabis

Chair:
  • Nicola Singleton (EMCDDA)
Speakers:
  • Alex Stevens (Kent Uni, ISSDP)
  • Simon Lenton (National Drug Research Institute, Curtin University – TBC)
    + other speakers based on abstracts selection

10.30-11.00             Coffee break

11.00-12.30

Prague Medical Cannabis Declaration 2017

Plenary session – Main hall, screening to halls 1 and 2

Medical Cannabis and Cannabinoids in the 21st century: what the medicine and the global control régime is to do. Public announcement of the objectives and “call to action” for every interested party.

Chair:
  • Steph Sherer (ASA & IMCPC)
Speakers:
  • Richard Rokyta (President of the Czech Medical Academy)
  • Michel Kazatchkine (member of the Global Commission on Drug Policy, and United Nations Secretary-General’s Special Envoy for AIDS in Eastern Europe and Central Asia)
  • Pavel Bém (Global Commission for Drug Policy)
  • Tomáš Zábranský (ResAd, ICCI)
  • Hana Vagnerova (KOPAC, Czech association of cannabis patients)

12.30 – 13.30          Lunch

13.30-15.00

Cannabis in the doctor’s office

Parallel session – main hall

How the medical practitioners shall approach new paradigm in the medicine. Where to get the newest information, how to acquire the best practices, how to talk to patients about the new medicines.

Chair:

Radovan Hřib (Chief Medical Doctor, Centre for Pain Treatment, St. Ann’s Faculty Hospital in Brno)

Speaker:

Eva Dokoupilová (rheumatologist, Chief medical doctor at the Medical Plus, ambulatory services, Uherské Hradiště)


Access research priority mapping

Parallel session – hall 1

There are three verticals in the medical cannabis research – medical biology, natural science, political science. The objective is to examine the empty spaces in all three verticals, find out the relations and specify the priorities where to aim the research first, so the most effective sequence can be maintained.

Chair:
  • Steph Sherer (Americans for Safe Access, and International Medical Cannabis Patients Consortium)
Speakers:
  • Ethan Russo (ICCI, Phytecs, Inc, formerly GW Pharmaceuticals)

+ other discussants based on abstracts selection


Outside the labs

Parallel session – hall 2

How the evidence-based medicine can learn from successful causal treatment cases of natural healers

Chair:
  • Tomáš Zábranský (ResAd, ICCI)
Speakers:
  • Jindřich Bayer, MA (Cure for Cancer: The Rick Simpson Protocol)

+ other discussants based on abstracts selection


15.00 – 15.30          Coffee break

15.30-17.00

Closing ceremony

Main hall, screening to halls 1 and 2

Results and outcomes. The future is bright, if we find the common ground. The movement cannot be stopped.

Chair:
  • Tomáš Zábranský (ResAd, ICCI)
Speakers:
  • Steph Sherer (Americans for Safe Access, and International Medical Cannabis Patients Consortium)
  • Lumír Ondřej Hanus (Hebrew University in Jerusalem, ICCI)